Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Instagram Outage Disrupts Thousands of U.S. Users 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
CAMBRIDGE, Mass., Sept. 20, 2017 -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the Ladenburg Thalmann 2017 Healthcare Conference at the Sofitel Hotel in New York City on Tuesday, Sept. 26, 2017, at 3:00 p.m. EDT.
The presentation will be webcast live at http://wsw.com/webcast/ladenburg3/vcel and may be accessed from the news and events section of the Vericel website.
About Vericel Corporation
Vericel develops, manufactures, and markets expanded autologous cell therapies for the treatment of patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Vericel is marketing MACI® (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Vericel is also marketing Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is developing ixmyelocel-T, an autologous multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit the company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2017 Vericel Corporation. All rights reserved.
Global Media Contacts:
David Schull
Russo Partners LLC
+1 212-845-4271 (office)
+1 858-717-2310 (mobile)
[email protected]
Karen Chase
Russo Partners LLC
+1 646-942-5627 (office)
+1 917-547-0434 (mobile)
[email protected]
Investor Contacts:
Chad Rubin
The Trout Group
[email protected]
+1 (646) 378-2947
Lee Stern
The Trout Group
[email protected]
+1 (646) 378-2922
